Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054812 | 0.84 | HTR1A (0.44) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4049636 | 0.81 | MEN1 (0.46) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4048748 | 0.80 | DRD2 (0.49) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4054675 | 0.80 | CHRNB4 (0.53) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4051310 | 0.80 | ALDH1A1 (0.51) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4222884 | 0.79 | TMEM97 (0.51) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4051698 | 0.79 | ALDH1A1 (0.50) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4046282 | 0.79 | ALDH1A1 (0.50) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4046988 | 0.79 | DRD2 (0.47) | DRD3HTR1AMEN1KMT2ACHRM2 | |
| SCHEMBL4705658 | 0.79 | DRD2 (0.53) | DRD3HTR1AMEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020409-A1 | New piperidinyl derivatives as modulators of chemokine receptor activity | AstraZeneca AB (SE) | 2009-02-04 | — | — | EP | claimed |
| EP-1421070-B1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | claimed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| EP-2020409-A1 | New piperidinyl derivatives as modulators of chemokine receptor activity | AstraZeneca AB (SE) | 2009-02-04 | — | — | EP | disclosed |
| EP-2020409-A1 | New piperidinyl derivatives as modulators of chemokine receptor activity | AstraZeneca AB (SE) | 2009-02-04 | — | — | EP | disclosed |
| EP-1421070-B1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | disclosed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | CCR2, CXCR1, CCR5 | HTR4 1101/4885DRD3 164/4885HTR1A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.